Anthem BioSciences Ltd (ANTH)

Currency in INR
936.95
-1.50(-0.16%)
Closed·
Advertisement
ANTHEM is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
932.00956.00
52 wk Range
579.15989.10
Key Statistics
Bid/Ask
933.60 / 936.95
Prev. Close
936.95
Open
938.05
Day's Range
932-956
52 wk Range
579.15-989.1
Volume
330.84K
Average Volume (3m)
660.85K
1-Year Change
38.01%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ANTHEM Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
974.25
Upside
+3.98%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high P/E ratio relative to near-term earnings growth

Anthem BioSciences Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral

Analyst Ratings

8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 974.25
(+3.98% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
JPMorgan
Buy1,000.00+6.73%900.00Maintain05/11/2026
Jefferies
Buy1,050.00+12.07%-New Coverage20/08/2026
JPMorgan
Buy900.00-3.94%850.00Maintain23/07/2026
Nomura/Instinet
Buy900.00-3.94%740.00Maintain22/05/2026
JPMorgan
Buy850.00-9.28%790.00Maintain21/05/2026

Anthem BioSciences Ltd Earnings Call Summary for Q2/2027

  • Q2 revenue rose 8% sequentially to INR 594 crore; EBITDA margin expanded to 50.6%, up from 43% in FY 2026, driven by cost discipline.
  • One late-stage molecule commercialized, bringing total to 15; five molecules launched in 18 months with $10B+ aggregate market potential.
  • Management expects double-digit growth long-term; Unit 4 Phase 1 capex at INR 1,200 crore, commissioning planned for March 2028.
  • Company shifting to 'solution provider' for complex molecules; reduced China sourcing to 20-21%, up domestic procurement to 75-78%.
  • Stock up 2.64% to $877 but down 50% over six months; analyst consensus at Hold amid customer concentration risk and new-tech monetization uncertainty.
Last Updated: 04/11/2026, 08:10
Read Full Transcript

Earnings

Latest Release
02/09/2026
EPS / Forecast
2.10 / 1.50
Revenue / Forecast
4.18B / 4.19B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 10.92
Dividend Yield
0.21%
Industry Median 0.64%
Annualised payout
2.00
Paid annually
5-Years Growth
-
Growth Streak

Compare ANTHEM to Peers and Sector

Metrics to compare
ANTHEM
Peers
Sector
Relationship
P/E Ratio
85.9x43.0x−0.2x
PEG Ratio
4.930.360.00
Price/Book
16.1x4.1x2.6x
Price / LTM Sales
25.7x6.8x2.8x
Upside (Analyst Target)
4.0%14.8%61.2%
Fair Value Upside
Unlock4.6%9.7%Unlock

Anthem Biosciences Limited operates as a contract research, development, and manufacturing organization in India, rest of Asia, North America, Europe, and internationally. It operates in two segments: Contract Manufacturing, Development & Discovery Services; and Speciality Ingredients. The company offers contract research development and manufacturing services, such as end-to-end services across the new chemical entity and new biological entity lifecycles, as well as engages in contract research, development, and manufacturing of development batches of molecules used for clinical trials up to commercial manufacturing for small molecules and biologics. It also manufactures and sells specialized fermentation-based active pharmaceutical ingredients, including probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars. The company was incorporated in 2006 and is based in Bengaluru, India.

Employees
2282
Market
India

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
71.93M12.77%67.40B
Other Institutional Investors
37.15M6.60%34.81B
Public Companies & Retail Investors
454.12M80.63%425.48B
Total
563.19M100.00%527.69B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Portsmouth Technologies LLC2.73%15,396,32714,425,589
HDFC Asset Management Company Limited2.28%12,816,94912,008,840

People Also Watch

1,928.80
SAIE
+1.24%
176.44
PINL
+0.31%
284.00
SADO
-2.79%
727.00
LENS
-0.06%

FAQ

What Is the Anthem BioSciences (NSE: ANTHEM) Share Price Today?

The Anthem BioSciences stock price today is 936.95 INR.

What Stock Exchange Does Anthem BioSciences (ANTHEM) Trade On?

Anthem BioSciences is listed and trades on the India National Stock Exchange.

What Is the Ticker (Stock Symbol) for Anthem BioSciences?

The stock symbol (also called a 'ticker') for Anthem BioSciences is "ANTHEM."

Does Anthem BioSciences Pay Dividends? What’s The Current ANTHEM Dividend Yield?

Yes, ANTHEM Pays Dividends to its Shareholders. The current Anthem BioSciences dividend yield is 0.2%%.

What Is the Current Anthem BioSciences Market Capitalisation?

As of today, Anthem BioSciences (NSE: ANTHEM) market cap is 527.69B INR.

What Is Anthem BioSciences's (ANTHEM) Earnings Per Share (TTM)?

The Anthem BioSciences EPS is currently 10.92 (Trailing Twelve Months).

When Is the Next Anthem BioSciences Earnings Date?

Anthem BioSciences's next earnings report will be released on 02/12/2026.

Is ANTHEM a Buy or Sell From a Technical Analyst Perspective?

Based on today's Anthem BioSciences moving averages and other technical indicators, the daily buy/sell signal for ANTHEM stock is Strong Buy.

How Many Times Has Anthem BioSciences Stock Split?

Anthem BioSciences has split 0 times. (See the ANTHEM stock split history page for full effective split date and price information.)

How Many Employees Does Anthem BioSciences Have?

Anthem BioSciences has 2282 employees, based on their latest Companies House report.

What is the current trading status of Anthem BioSciences (NSE: ANTHEM)?

As of 15/11/2026, Anthem BioSciences (ANTHEM) is trading at a share price of 936.95 INR, with a previous close of 936.95 INR. The stock has fluctuated within a day range of 932.00 INR to 956.00 INR, while its 52-week range spans from 579.15 INR to 989.10 INR.

What Is Anthem BioSciences (ANTHEM) Price Target According to Analysts?

The average 12-month price target for Anthem BioSciences is 974.25 INR, with a high estimate of 1063 INR and a low estimate of 850 INR. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +3.98% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.